Shorts

0:49
Proactive Supportive Care Is Key With Bispecific Therapy
3 months ago
by
Natasha Edwin, MD

0:58
Why General-Purpose AI Doesn’t Cut It for Oncology
3 months ago
by
Shaalan Beg, MD, MBA, FASCO

0:35
Tocilizumab May Ease Bispecific Uptake in Community Practice
3 months ago
by
Natasha Edwin, MD

1:17
Navigating Early Treatment Access After Promising Trial Data
3 months ago
by
David Savage, MD, PhD

0:35
Your Wednesday Wrap-Up - August 19
3 months ago
by
Sabrina Serani

0:35
Why "Asian American" Isn't Just One Medical Category
3 months ago
by
Scarlett Lin Gomez, PhD, MPH

0:42
Targeting Breast Cancer's Nerve Connection
3 months ago
by
Jumana Abbadi, MD

0:32
A Surprising New Insight on How Breast Cancer Spreads
3 months ago

0:46
Can Operations Keep Pace With Oncology’s Outpatient Expansion?
3 months ago
by
Donna Berizzi, RN, DNP, OCN, NEA-BC

1:17
The Link Between Inflammation, Aging, and Cancer
3 months ago
by
Hearn Jay Cho, MD, PhD

0:34
An Often-Missed Early Step in Myeloma Care
3 months ago
by
Sagar Lonial, MD

0:17
Your Wednesday Wrap-Up - August 12th
3 months ago

0:34
Can We Cure Lung Cancer With Shorter Immunotherapy Treatment?
3 months ago
by
Ravi Salgia, MD, PhD

0:54
The Growing Case for ePROs in Community Oncology
3 months ago
by
Debra Patt, MD, PhD, MBA

0:50
Does ENDURANCE Support Lenalidomide Discontinuation At 2 Years?
3 months ago
by
Sagar Lonial, MD

0:41
OncoPRO Helps Practices Navigate ePRO Adoption
3 months ago
by
Debra Patt, MD, PhD, MBA

0:43
Can We Make Stage IV Lung Cancer Curable? New Research Offers Hope
3 months ago
by
Ravi Salgia, MD, PhD

0:36
ePRO Monitoring: Earlier Intervention, Fewer Hospitalizations
3 months ago
by
Debra Patt, MD, PhD, MBA

0:30
Why the Future of Oncology Looks Brighter Than Ever
3 months ago
by
Ravi Salgia, MD, PhD

0:43
The Future of Myeloma Care: Home Administration
3 months ago
by
Joseph Mikhael, MD

0:35
GLP-1s Linked to 34% Lower Cancer Mortality Rate
3 months ago
by
Jess Paulus, ScD

0:26
Your Wednesday Wrap-Up
3 months ago
by
Sabrina Serani

1:08
Reacting to the FDA Advisory Committee Verdict on RP1 in Melanoma
3 months ago
by
Vincent Ma, MD

0:42
Could GLP-1s Have Anticancer Effects?
3 months ago
by
Jess Paulus, ScD

1:04
Breaking Free From Infusion Centers With SC Myeloma Treatment
3 months ago
by
Joseph Mikhael, MD

0:35
Breakthough in Long-Term TNBC Management With KEYNOTE-522
3 months ago
by
Javier Cortés, MD, PhD

0:31
Why Standardized Oncology Care is a Global Necessity
3 months ago
by
Daniel Araujo, MD

0:42
Uncovering the Secrets of Tumor Resistance
3 months ago
by
Edgardo Santos Castillero, MD, FACP, FASCO

0:50
Is Oncology Ready for Multi-Cancer Blood Tests?
4 months ago
by
Ranjit Goudar, MD

0:50
Most Women Don't Know This Major Cancer Risk
4 months ago
by
Darren Mays, PhD, MPH
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC
2
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
3
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
4
FDA Fast Tracks Elticertinib for Previously Treated EGFR Exon 20 NSCLC
5
